<DOC>
	<DOCNO>NCT01683773</DOCNO>
	<brief_summary>This trial investigate administration two new tuberculosis vaccine , call AERAS-402 MVA85A . The purpose trial ass happen vaccine give one . The trial ass safety vaccine also ability stimulate immune response within body . It hop two vaccine give sequence , combine immune response even well vaccine use individually .</brief_summary>
	<brief_title>Safety Study Tuberculosis Vaccines AERAS-402 MVA85A</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects must meet follow criterion enter trial : Healthy adult age 1855 year Resident near Oxford ( CCVTM ) Birmingham ( WTCRF ; able travel Oxford vaccination ) duration trial period No relevant finding medical history physical examination Confirmation prior vaccination BCG le 6 month prior project trial vaccination date ( visible BCG scar examination write documentation ) Allow Investigators discuss individual 's medical history GP Use effective contraception duration trial period ( female ) Refrain blood donation trial Give write informed consent Allow Investigator register subject detail confidential database prevent concurrent entry clinical trial Agrees avoid elective surgery duration trial Has body mass index ( BMI ) 18 33 ( weight/height2 ) nomogram Able willing ( Investigator 's opinion ) comply trial requirement Subjects must meet none follow criterion enter trial : Laboratory evidence screen latent M. tb infection indicate positive ELISPOT response ESAT6 CFP10 antigens Clinical , radiological , laboratory evidence current active TB disease Shared residence within one year prior day 0 individual antituberculosis treatment culture smearpositive pulmonary tuberculosis Previous treatment active latent tuberculosis infection Received TST within 90 day prior day 0 Received systemic antibiotic within 14 day prior day 0 Inability discontinue daily medication follow trial : oral contraceptive , vitamin , nonprescription nutritional supplement , aspirin , antihistamine , antihypertensive , antidepressant , inhaled steroid , bronchodilator , stable , regular medication deem impact safety immunogenicity . Previous vaccination candidate vaccine MVA85A candidate vaccine FP85A recombinant MVA adenoviral vaccine ; AERAS402 ; investigational M. tb vaccine Clinically significant history skin disorder , allergy , immunodeficiency ( include HIV ) , autoimmune disease , cancer ( except BCC CIS ) , cardiovascular disease , gastrointestinal disease , liver disease , renal disease , endocrine disorder , neurological illness , psychiatric disorder , drug alcohol abuse History serious psychiatric condition Concurrent oral systemic steroid medication concurrent use immunosuppressive agent History anaphylaxis vaccination allergy likely exacerbate component trial vaccine , include egg Any abnormality screen blood urine test deem clinically significant may compromise safety subject triala Positive HBsAg , HCV HIV antibody Female currently lactate , confirmed pregnancy intention become pregnant trial period Use investigational medicinal product nonregistered drug , live vaccine , medical device trial vaccine 30 day prior dose trial vaccine , plan use trial period Administration immunoglobulins and/or blood product within three month precede plan trial vaccination date Any significant disease , disorder , finding , , opinion Investigator , may either put subject risk may influence result trial may affect subject 's ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Phase I</keyword>
	<keyword>MVA85A</keyword>
	<keyword>AERAS-402</keyword>
</DOC>